American Association for Cancer Research

Cancer Drug Development-NCI Partnership with Industry

 
AACR Science Policy Forum (slides only)
Monday, April 20, 2009
1:30 p.m. - 3:00 p.m.                                                 
Room 607, Colorado Convention Center

 

Cancer Drug Development as a Successful Public-Private Enterprise: The NCI in Partnership with Industry (slides only)

Co-Chairs: Miguel A. Villalona-Calero, The Ohio State University, Columbus, OH; James A. Zwiebel, Chief, Investigational Drug Branch, NCI, Bethesda, MD

The development of new anticancer agents is a crucial process to win the battle against cancer. Unfortunately, few efficacious agents emerge each year with the potential to make a difference in patients' lives. The principal stakeholders in the drug development process are industry, academic institutions and The National Cancer Institute. Developing successful collaborations among these three entities should accelerate drug discovery, optimization, production and evaluation in preclinical models and humans, making successful drugs available to patients earlier and in larger numbers. It is very important to avoid duplicative work and to concentrate the different steps on the individualized continuum for each drug to the groups with the expertise to deliver quick and valid results. This session will foster dialog between industry and government with input from the academic community. We will discuss initiatives from the NCI to facilitate the success of compounds coming from industry and will engage the audience to discover needs and other potential initiatives that the NCI can make available to industry and academic investigators.

1:30   Introduction and Opening Remarks: James A. Zwiebel

1:40   The NCI Developmental Therapeutics Program - from Molecules to Medicines: Jerry Collins, Developmental Therapeutics Program DCTD, NCI

1:50   The NCI Cancer Imaging Program - Developing Imaging Tools for Drug Development: Paula Jacobs, Cancer Imaging Program, DCTD, NCI

2:00   The NCI Experimental Therapy Program - Biomarker Assay Validation and Phase 0 Trials: Joseph Tomaszewski, Office of the Director, DCTD

2:10   The NCI Cancer Therapy Evaluation Program - Therapeutics in the Public Interest: Jeffrey Abrams, CTEP, DCTD, NCI

2:20   Collaborative Drug Development with the NCI - an Industry Perspective: David Schenkein, Genentech

2:30   Panel Discussion:  All speakers and co-chairs, plus Merrill J. Egorin, University of Pittsburgh School of Medicine (no slides)